Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
22.30
-1.07 (-4.58%)
At close: Mar 20, 2026, 4:00 PM EDT
22.63
+0.33 (1.48%)
After-hours: Mar 20, 2026, 5:07 PM EDT
Zenas BioPharma Revenue
In the year 2025, Zenas BioPharma had annual revenue of $10.00M with 100.00% growth.
Revenue (ttm)
$10.00M
Revenue Growth
+100.00%
P/S Ratio
127.92
Revenue / Employee
$59,880
Employees
167
Market Cap
1.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | 5.00M | 100.00% |
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 4 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewsWire
- 6 weeks ago - Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 2 months ago - Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript - Seeking Alpha
- 2 months ago - Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga